- A “Certified-Organic-style” third-party safety-and-efficacy mark for medicine was proposed as a libertarian alternative to the FDA; the discussion centered on how to avoid re-creating the same bureaucratic or rent-seeking problems and how to bootstrap credibility when early adopters have no market signal.  
- Participants noted that the FDA itself does not run tests but enforces costly clinical-trial rules backed by legal force, creating a de-facto barrier that favors large pharma and pushes experimentation offshore or into DIY.  
- Medical tourism plus an independent certification stamp (e.g., “med-QAI”) was floated as a practical path: run trials in unregulated jurisdictions, accumulate real-world evidence, and later compel regulators to accept the data once outcomes are undeniable.  
- Eli sketched a continuum-of-approval model in which drugs or devices carry granular labels (p-values, trial phases completed, recalls, etc.) analogous to supplement certifications, arguing that OECD mutual-recognition could create regulatory competition and reduce duplication.  
- A blockchain-based, opt-in national epidemiology database was proposed: patients donate lifelong, anonymized health data to expose drug–drug interactions and improve public-health decisions; technical ideas included QR-code private keys and zero-knowledge analytics to preserve privacy.  
- RangerMauve and nsh debated practical data-sovereignty architectures—patient-owned encrypted archives, P2P transfer protocols, and auditable zero-knowledge computation—as ways to bypass entrenched EMR monopolies and their high interoperability fees.  
- cslr introduced open-source EEG-driven audio–visual neurofeedback software that uses reinforcement learning to steer brainwaves; skepticism was voiced about safety, source availability, and potential dual-use for coercion.  
- A Bloomberg article on E11 Bio (ex-Google CEO funding viral brain-circuit mapping) was shared as an example of high-profile, well-funded neuro-intervention research that skirts traditional regulatory paths.  
- Tokenized uranium (uranium_io) was briefly linked as an instance of financializing physical commodities, illustrating broader trends in decentralized asset markets.  
- The conversation closed with reflections on systemic incentives: regulators face only downside risk for approvals, consumers are conditioned to trust authority rather than evaluate evidence, and any reform must either route around the state or enlist it under fiscal pressure as Medicare solvency erodes in the 2030s.